ZILRETTA
Peaktriamcinolone acetonide extended-release injectable suspension
NDAINTRA-ARTICULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZILRETTA is an extended-release intra-articular suspension of triamcinolone acetonide, a corticosteroid designed for single-injection treatment of knee osteoarthritis pain. It delivers sustained anti-inflammatory activity directly into the joint, reducing symptoms with a one-time administration rather than repeated injections.
$0.01BPart D
Peak5.2 years to LOEPeak-stage product with minimal Medicare Part D penetration suggests mature market with limited growth runway; commercial teams are stabilizing market position rather than expanding.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZILRETTA offers career opportunities primarily in commercial execution and market maintenance roles, as the product is at peak lifecycle with limited clinical development. Working on this brand emphasizes sales excellence, physician engagement, and operational efficiency rather than innovation or expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.